{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:54:05Z","timestamp":1789016045296,"version":"build-2803163510"},"reference-count":39,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T00:00:00Z","timestamp":1588118400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007903","name":"Bloodwise","doi-asserted-by":"publisher","award":["LLR 04\/058"],"award-info":[{"award-number":["LLR 04\/058"]}],"id":[{"id":"10.13039\/501100007903","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["eJHaem"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Outcomes after frontline treatment of Burkitt lymphoma (BL) have improved with the introduction of dose\u2010intense chemotherapy regimens, such as CODOX\u2010M\/IVAC. While rituximab has increased survival rates for most forms of high\u2010grade B\u2010cell lymphoma, there has previously been hesitancy about incorporating it into BL treatment, partly due to concerns about increased toxicity. Prospective data using the standard dose CODOX\u2010M\/IVAC regimen in combination with rituximab are lacking. We conducted a single\u2010arm phase 2 trial to assess the efficacy and toxicity of R\u2010CODOX\u2010M\/R\u2010IVAC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Eligible patients were aged 18\u201365 years, with newly diagnosed BL with <jats:italic>MYC<\/jats:italic> rearrangement as the sole cytogenetic abnormality, and high\u2010risk disease, defined by an International Prognostic Index (IPI) score of 3\u20105. Patients received two cycles of R\u2010CODOX\u2010M chemotherapy alternating with two cycles of R\u2010IVAC, followed by two further cycles of rituximab alone. The primary endpoint was 2\u2010year progression\u2010free survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Thirty\u2010eight patients were registered but after central pathology review, 27 patients had confirmed BL and commenced study treatment. Median age was 35 years, 14.8% patients had central nervous system involvement and 18.5% were HIV positive. Twenty\u2010two (81.4%) patients completed four cycles of chemotherapy. There were two treatment\u2010related deaths (7.4%). Two\u2010year progression\u2010free and overall survival rates were 77.2% (90% confidence interval [CI]: 56.0\u201089.0) and 80.7% (90% CI: 59.6\u201091.5), respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This prospective trial demonstrates excellent survival rates with R\u2010CODOX\u2010M\/R\u2010IVAC in a high\u2010risk BL cohort. It provides reassuring evidence regarding the feasibility of this regimen and also provides a benchmark for future studies.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jha2.3","type":"journal-article","created":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T11:41:00Z","timestamp":1588160460000},"page":"133-141","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Favourable outcomes for high\u2010risk Burkitt lymphoma patients (IPI 3\u20105) treated with rituximab plus CODOX\u2010M\/IVAC: Results of a phase 2 UK NCRI trial"],"prefix":"10.1002","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9316-7544","authenticated-orcid":false,"given":"Elizabeth H.","family":"Phillips","sequence":"first","affiliation":[{"name":"Division of Cancer Sciences the University of Manchester  Manchester UK"},{"name":"Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute University College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Burton","sequence":"additional","affiliation":[{"name":"HMDS, St James's University Hospital  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy A.","family":"Kirkwood","sequence":"additional","affiliation":[{"name":"Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute University College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Barrans","sequence":"additional","affiliation":[{"name":"HMDS, St James's University Hospital  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Lawrie","sequence":"additional","affiliation":[{"name":"Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute University College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Rule","sequence":"additional","affiliation":[{"name":"Plymouth University Medical School  Plymouth UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Patmore","sequence":"additional","affiliation":[{"name":"Haematology Department, Castle Hill Hospital  Hull UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9948-660X","authenticated-orcid":false,"given":"Ruth","family":"Pettengell","sequence":"additional","affiliation":[{"name":"Clinical Sciences Department, St George's University of London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirit M.","family":"Ardeshna","sequence":"additional","affiliation":[{"name":"Haematology Department University College Hospital London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Montoto","sequence":"additional","affiliation":[{"name":"Haemato\u2010oncology Department Barts Health NHS Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankara","family":"Paneesha","sequence":"additional","affiliation":[{"name":"Haematology Department Heart of England NHS Trust  Birmingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Clifton\u2010Hadley","sequence":"additional","affiliation":[{"name":"Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute University College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9988-5528","authenticated-orcid":false,"given":"David C.","family":"Linch","sequence":"additional","affiliation":[{"name":"UCL Cancer Institute University College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew K.","family":"McMillan","sequence":"additional","affiliation":[{"name":"Haematology Department Nottingham University Hospitals NHS Trust  Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,4,29]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-145128"},{"key":"e_1_2_8_3_1","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow SH","year":"2008"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-563627"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910170407"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24720"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.9.2465"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-12-475558"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08877.x"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi403"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20143"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.3.664.bloodjournal853664"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/1042819031000141301"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.3.925"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf253"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10495-006-6314-5"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01317-3"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21776"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_8_24_1","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s11845-015-1288-3","article-title":"Burkitt leukaemia\/lymphoma: R\u2010CODOX\u2010M\/R\u2010IVAC remains gold standard treatment in BL","volume":"185","author":"Smyth L","year":"2016","journal-title":"Ir J Med Sci"},{"key":"e_1_2_8_25_1","article-title":"Excellent real\u2010world outcomes of adults with Burkitt lymphoma treated with CODOX\u2010M\/IVAC plus or minus rituximab","author":"Zhu KY","year":"2018","journal-title":"Br. J. Haematol"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq677"},{"key":"e_1_2_8_27_1","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2019-122971","article-title":"The evaluation and treatment (Tx) of Burkitt lymphoma (BL) in the modern era: real world (RW) outcomes and prognostication across 26 US Cancer Centers (CC)","volume":"134","author":"Evens AM","year":"2019","journal-title":"Blood"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70235-2"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000623"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08447.x"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt414"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-623900"},{"key":"e_1_2_8_33_1","first-page":"188","article-title":"Risk\u2010adapted therapy in adults with Burkitt lymphoma: results of NCI 9177, a multicenter prospective phase II study of DA\u2010EPOCH\u2010R","volume":"130","author":"Roschewski M","year":"2017","journal-title":"Blood"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.086827"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12736"},{"key":"e_1_2_8_36_1","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1182\/blood-2019-122990","article-title":"Outcomes of patients with newly\u2010diagnosed Burkitt lymphoma (BL) and central nervous system (CNS) involvement treated in the modern era: a multi\u2010institutional real\u2010world analysis","volume":"134","author":"Zayac A","year":"2019","journal-title":"Blood"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1308392"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3167-7"},{"key":"e_1_2_8_39_1","first-page":"S1548","article-title":"Favourable outcomes with R\u2010CODOX\u2010M\/R\u2010IVAC across all subgroups of aggressive high grade B\u2010cell lymphoma: pathology and updated survival results from a phase 2 UK NCRI\/LLR trial","volume":"2","author":"Phillips E","year":"2018","journal-title":"Hemasphere"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008304329943"}],"container-title":["eJHaem"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjha2.3","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.3","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jha2.3","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T05:17:36Z","timestamp":1693891056000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jha2.3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,29]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["10.1002\/jha2.3"],"URL":"https:\/\/doi.org\/10.1002\/jha2.3","archive":["Portico"],"relation":{},"ISSN":["2688-6146","2688-6146"],"issn-type":[{"value":"2688-6146","type":"print"},{"value":"2688-6146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,29]]},"assertion":[{"value":"2020-03-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}